Antibiotic use and resistance in public-sector hospitals in KwaZulu-Natal

South African Medical Journal

Volumn 95, Issue 11 I, 2005, Pages 865-870

  Essack, S Y ^a   Connolly, C ^b   Sturm, A W ^c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM; BETA LACTAMASE; BETA LACTAMASE AMPC; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFRADINE; CEFTAZIDIME; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; MEROPENEM; NALIDIXIC ACID; NITROFURANTOIN; OXACILLIN; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; DRUG UTILIZATION; HEALTH CARE SYSTEM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PUBLIC HOSPITAL; SOUTH AFRICA;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG UTILIZATION; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HOSPITALS, PUBLIC; HUMANS; POPULATION SURVEILLANCE; SOUTH AFRICA;

EID: 28044446351     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hunter PA, Reeves DS. The current status of resistance to antimicrobial agents: report on a meeting. J Antimicrob Chemother 2002; 49: 17-23.
2. Dudley M. Bacterial resistance mechanisms to β-lactam antibiotics, assessment of management strategies. Pharmacotherapy 1995; 15(1); Suppl, 59-514.
3. Sanders CC, Sanders WE Jun. β-lactam resistance in Gram-negative bacteria, global trends and clinical impact. Clin Infect Dis 1992; 15: 824-839.
4. Spratt BG. Resistance to antibiotics mediated by target alterations. Science 1994; 264; 388-393.
5. Kolar M, Urbanek K, Latal T. Antibiotic selective pressure and the development of bacterial resistance. Int J Antimicrob Agents 2001; 17: 357-363.
6. Kohneman E, Allen S, Janda W, Schreckenberger P, Winn W jun., eds. Diagnostic Microbiology. 5th ed. American Society for Microbiology, Philadelphia: Lippincott, Williams & Wilkins, 1993.
7. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Approved standard M7-A2. National Committee for Clinical Laboratory Standards, Villanova, Pa: 1994.
8. Brown DFJ. Detection of methicillin/oxacillin resistance in staphylococci. J Antimicrob Chemother 2001; 48: Suppl. S1, 65-70.
9. Moland ES, Thomson KS. Extended-spectrum β-lactamases of Enterobacteriaceae. J Antimicrob Chemother 1994; 33: 666-668.
10. National Nosocomial Infections Surveillance (NNIS) System. Intensive care antimicrobial resistance epidemiology (ICARE) surveillance report, data summary from January 1996 through December 1997. Special Report of the NNIS June, 279-284.
11. Pillay T, Pillay DG, Adhikari M, Sturm AW. Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates. Am J Perinatol 1998; 15: 47-51.
12. Karas JA, Pillay DG, Sturm AW. Treatment failure due to extended-spectrum beta-lactamase. J Antimicrob Chemother 1996; 37: 203-204.
13. Schlemmer B. Impact of registration procedures on antibiotic policies. Clinical Microbiology and Infection 2001; 7: Suppl. 6, 5-8.
14. Sorberg M, Farra A, Ransjo U, et al. Long-term antibiotic resistance surveillance of gram-negative pathogens suggests that temporal trends can be used as a resistance warning system. Scand J Infect Dis 2002; 34: 372-378.
15. Blondeau JM, Tillotson GS. Formula to help select rational antimicrobial therapy (FRST): its application to community- and hospital-acquired urinary tract infections. Int J Antimicrob Agents 1999; 12: 145-150.